SREBF2 and prostate carcinoma: In prostate cancer, PTEN/p53 deficiencies activate SREBP2 transcription, upregulating SQLE, and enhance SQLE protein stability through inhibition of the PI3K/Akt/GSK3β‐mediated proteasomal pathway.